ABSTRACT
Objective Health systems rely on multiple approaches for population-level risk stratification/management. However, they can under-represent members with rising risk and complex treatment needs. To address these gaps and broaden the coverage of members at risk, we present an accretive framework of six predictive models across complementary risk measures for population-level stratification/management.
Materials and Methods Logistic regression models were trained/tested for six outcomes across cost (rising and elevated cost), utilization (rising and elevated utilization), and chronic-disease related (multimorbidities and polypharmacy) risk measures in 2016 using claims-based features from 2015 for ∼8.97 million members in a nation-wide administrative claims database. Model performances were validated against a holdout cohort of ∼2.99 million members. The presence/absence of each outcome prediction for members was summed into an accretive predictive risk index (aPRI) for population-level risk stratification evaluation.
Results Integrating predictions from the six models enabled member stratification across risk measures including future costs, utilizations, and comorbidities. Each of the risk predictions is represented in aPRI levels 0– 6, and their underlying model probabilities/risk measures increase with increasing aPRI levels. ∼83% of members grouped into a “low risk” (aPRI = 0) or “rising risk” category (aPRI = 1 - 2) and ∼17% into a “high risk” (aPRI = 3 - 6) category. Overlap/correlation analyses of risk predictions and comparison of their drivers further support the complementarity of predictions within aPRI and its enhanced coverage of members at risk.
Discussion By integrating targeted and complementary risk predictions, aPRI enhances current population-level risk stratification approaches.
Conclusion We have developed an accretive predictive modeling framework for enhanced population-level risk stratification/management.
Competing Interest Statement
All authors are current or former employees at Geneia LLC
Funding Statement
No external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Geneia Research Ethics Committee determined no ethics approval required
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
♦ Certain data used in this study were supplied by International Business Machines Corporation. Any analysis, interpretation, or conclusion based on these data is solely that of the authors and not International Business Machines Corporation.
Data Availability
The data used for this manuscript are commercially licensed and not publicly available.
